PG
PCRX icon

Patten Group’s Pacira BioSciences PCRX Stock Holding History

Patten Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-55
Closed -$2K – 636
2017
Q3 		$2K Hold
55
– – ﹤0.01% 589
2017
Q2 		$2K Hold
55
– – ﹤0.01% 605
2017
Q1 		$3K Hold
55
– – ﹤0.01% 567
2016
Q4 		$2K Hold
55
– – ﹤0.01% 570
2016
Q3 		$1.83K Hold
55
– – ﹤0.01% 593
2016
Q2 		$1.85K Hold
55
– – ﹤0.01% 590
2016
Q1 		$2.91K Hold
55
– – ﹤0.01% 579
2015
Q4 		$4.22K Hold
55
– – ﹤0.01% 581
2015
Q3 		$2.26K Hold
55
– – ﹤0.01% 546
2015
Q2 		$3.89K Buy
+55
New +$4.33K ﹤0.01% 526

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Patten Group's PCRX Position: Q4 2017 in Review

Patten Group sold out of Pacira BioSciences (PCRX) in Q4 2017, closing a stake of 55 shares — an estimated $2K sold.

Patten Group first reported a position in PCRX in Q2 2015 and held it in 10 quarters. The position peaked at $4.22K in Q4 2015. 185 funds tracked by Wall St. Rank hold PCRX as of Q4 2017.

  • Patten Group reported no remaining Pacira BioSciences position as of Q4 2017 after selling out during the quarter.
  • Patten Group sold 55 Pacira BioSciences shares in Q4 2017, an estimated $2K.
  • Patten Group first reported a position in Pacira BioSciences in Q2 2015 and held it in 10 quarters.
  • Patten Group's Pacira BioSciences position peaked at $4.22K in Q4 2015.
  • 185 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2017.

Based on Patten Group's 13F filing for Q4 2017, filed 2 Feb 2018.